Cargando…
Changes in CSF sPDGFRβ level and their association with blood–brain barrier breakdown in Alzheimer’s disease with or without small cerebrovascular lesions
BACKGROUND: CSF-soluble platelet-derived growth factor receptor beta (sPDGFRβ) is closely associated with pericyte damage. However, the changes in CSF sPDGFRβ levels and their role in blood–brain barrier (BBB) leakage at different stages of Alzheimer’s disease (AD), with or without cerebral small ve...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012584/ https://www.ncbi.nlm.nih.gov/pubmed/36915135 http://dx.doi.org/10.1186/s13195-023-01199-5 |
_version_ | 1784906632615952384 |
---|---|
author | Lv, Xinyi Zhang, Mengguo Cheng, Zhaozhao Wang, Qiong Wang, Peng Xie, Qiang Ni, Ming Shen, Yong Tang, Qiqiang Gao, Feng |
author_facet | Lv, Xinyi Zhang, Mengguo Cheng, Zhaozhao Wang, Qiong Wang, Peng Xie, Qiang Ni, Ming Shen, Yong Tang, Qiqiang Gao, Feng |
author_sort | Lv, Xinyi |
collection | PubMed |
description | BACKGROUND: CSF-soluble platelet-derived growth factor receptor beta (sPDGFRβ) is closely associated with pericyte damage. However, the changes in CSF sPDGFRβ levels and their role in blood–brain barrier (BBB) leakage at different stages of Alzheimer’s disease (AD), with or without cerebral small vessel disease (CSVD) burden, remain unclear. METHODS: A total of 158 individuals from the China Aging and Neurodegenerative Disorder Initiative cohort were selected, including 27, 48, and 83 individuals with a clinical dementia rating (CDR) score of 0, 0.5, and 1–2, respectively. CSF total tau, phosphorylated tau181 (p-tau181), Aβ40, and Aβ42 were measured using the Simoa assay. Albumin and CSF sPDGFRβ were measured by commercial assay kits. CSVD burden was assessed by magnetic resonance imaging. RESULTS: CSF sPDGFRβ was the highest level in the CDR 0.5 group. CSF sPDGFRβ was significantly correlated with the CSF/serum albumin ratio (Q-alb) in the CDR 0–0.5 group (β = 0.314, p = 0.008) but not in the CDR 1–2 group (β = − 0.117, p = 0.317). In the CDR 0–0.5 group, CSF sPDGFRβ exhibited a significant mediating effect between Aβ42/Aβ40 levels and Q-alb (p = 0.038). Q-alb, rather than CSF sPDGFRβ, showed a significant difference between individuals with or without CSVD burden. Furthermore, in the CDR 0.5 group, CSF sPDGFRβ was higher in subjects with progressive mild cognitive impairment than in those with stable mild cognitive impairment subjects (p < 0.001). Meanwhile, CSF sPDGFRβ was significantly associated with yearly changes in MMSE scores in the CDR 0.5 group (β = − 0.400, p = 0.020) and CDR 0.5 (A+) subgroup (β = − 0.542, p = 0.019). CONCLUSIONS: We provide evidence that increased CSF sPDGFRβ is associated with BBB leakage in the early cognitive impairment stage of AD, which may contribute to cognitive impairment in AD progression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01199-5. |
format | Online Article Text |
id | pubmed-10012584 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100125842023-03-15 Changes in CSF sPDGFRβ level and their association with blood–brain barrier breakdown in Alzheimer’s disease with or without small cerebrovascular lesions Lv, Xinyi Zhang, Mengguo Cheng, Zhaozhao Wang, Qiong Wang, Peng Xie, Qiang Ni, Ming Shen, Yong Tang, Qiqiang Gao, Feng Alzheimers Res Ther Research BACKGROUND: CSF-soluble platelet-derived growth factor receptor beta (sPDGFRβ) is closely associated with pericyte damage. However, the changes in CSF sPDGFRβ levels and their role in blood–brain barrier (BBB) leakage at different stages of Alzheimer’s disease (AD), with or without cerebral small vessel disease (CSVD) burden, remain unclear. METHODS: A total of 158 individuals from the China Aging and Neurodegenerative Disorder Initiative cohort were selected, including 27, 48, and 83 individuals with a clinical dementia rating (CDR) score of 0, 0.5, and 1–2, respectively. CSF total tau, phosphorylated tau181 (p-tau181), Aβ40, and Aβ42 were measured using the Simoa assay. Albumin and CSF sPDGFRβ were measured by commercial assay kits. CSVD burden was assessed by magnetic resonance imaging. RESULTS: CSF sPDGFRβ was the highest level in the CDR 0.5 group. CSF sPDGFRβ was significantly correlated with the CSF/serum albumin ratio (Q-alb) in the CDR 0–0.5 group (β = 0.314, p = 0.008) but not in the CDR 1–2 group (β = − 0.117, p = 0.317). In the CDR 0–0.5 group, CSF sPDGFRβ exhibited a significant mediating effect between Aβ42/Aβ40 levels and Q-alb (p = 0.038). Q-alb, rather than CSF sPDGFRβ, showed a significant difference between individuals with or without CSVD burden. Furthermore, in the CDR 0.5 group, CSF sPDGFRβ was higher in subjects with progressive mild cognitive impairment than in those with stable mild cognitive impairment subjects (p < 0.001). Meanwhile, CSF sPDGFRβ was significantly associated with yearly changes in MMSE scores in the CDR 0.5 group (β = − 0.400, p = 0.020) and CDR 0.5 (A+) subgroup (β = − 0.542, p = 0.019). CONCLUSIONS: We provide evidence that increased CSF sPDGFRβ is associated with BBB leakage in the early cognitive impairment stage of AD, which may contribute to cognitive impairment in AD progression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01199-5. BioMed Central 2023-03-14 /pmc/articles/PMC10012584/ /pubmed/36915135 http://dx.doi.org/10.1186/s13195-023-01199-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Lv, Xinyi Zhang, Mengguo Cheng, Zhaozhao Wang, Qiong Wang, Peng Xie, Qiang Ni, Ming Shen, Yong Tang, Qiqiang Gao, Feng Changes in CSF sPDGFRβ level and their association with blood–brain barrier breakdown in Alzheimer’s disease with or without small cerebrovascular lesions |
title | Changes in CSF sPDGFRβ level and their association with blood–brain barrier breakdown in Alzheimer’s disease with or without small cerebrovascular lesions |
title_full | Changes in CSF sPDGFRβ level and their association with blood–brain barrier breakdown in Alzheimer’s disease with or without small cerebrovascular lesions |
title_fullStr | Changes in CSF sPDGFRβ level and their association with blood–brain barrier breakdown in Alzheimer’s disease with or without small cerebrovascular lesions |
title_full_unstemmed | Changes in CSF sPDGFRβ level and their association with blood–brain barrier breakdown in Alzheimer’s disease with or without small cerebrovascular lesions |
title_short | Changes in CSF sPDGFRβ level and their association with blood–brain barrier breakdown in Alzheimer’s disease with or without small cerebrovascular lesions |
title_sort | changes in csf spdgfrβ level and their association with blood–brain barrier breakdown in alzheimer’s disease with or without small cerebrovascular lesions |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012584/ https://www.ncbi.nlm.nih.gov/pubmed/36915135 http://dx.doi.org/10.1186/s13195-023-01199-5 |
work_keys_str_mv | AT lvxinyi changesincsfspdgfrblevelandtheirassociationwithbloodbrainbarrierbreakdowninalzheimersdiseasewithorwithoutsmallcerebrovascularlesions AT zhangmengguo changesincsfspdgfrblevelandtheirassociationwithbloodbrainbarrierbreakdowninalzheimersdiseasewithorwithoutsmallcerebrovascularlesions AT chengzhaozhao changesincsfspdgfrblevelandtheirassociationwithbloodbrainbarrierbreakdowninalzheimersdiseasewithorwithoutsmallcerebrovascularlesions AT wangqiong changesincsfspdgfrblevelandtheirassociationwithbloodbrainbarrierbreakdowninalzheimersdiseasewithorwithoutsmallcerebrovascularlesions AT wangpeng changesincsfspdgfrblevelandtheirassociationwithbloodbrainbarrierbreakdowninalzheimersdiseasewithorwithoutsmallcerebrovascularlesions AT xieqiang changesincsfspdgfrblevelandtheirassociationwithbloodbrainbarrierbreakdowninalzheimersdiseasewithorwithoutsmallcerebrovascularlesions AT niming changesincsfspdgfrblevelandtheirassociationwithbloodbrainbarrierbreakdowninalzheimersdiseasewithorwithoutsmallcerebrovascularlesions AT shenyong changesincsfspdgfrblevelandtheirassociationwithbloodbrainbarrierbreakdowninalzheimersdiseasewithorwithoutsmallcerebrovascularlesions AT tangqiqiang changesincsfspdgfrblevelandtheirassociationwithbloodbrainbarrierbreakdowninalzheimersdiseasewithorwithoutsmallcerebrovascularlesions AT gaofeng changesincsfspdgfrblevelandtheirassociationwithbloodbrainbarrierbreakdowninalzheimersdiseasewithorwithoutsmallcerebrovascularlesions AT changesincsfspdgfrblevelandtheirassociationwithbloodbrainbarrierbreakdowninalzheimersdiseasewithorwithoutsmallcerebrovascularlesions |